Grifols, S.A.
https://www.grifols.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grifols, S.A.
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
GC Pharma Preps For Life After Sale Of North American Subsidiaries
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
Coronavirus Notebook: A UK Catapult, A Russian Vaccine, And A Cuban Therapy
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
GC Pharma Sells N American Plasma Units To Grifols As Pandemic Prolongs
The South Korean pharma firm, which has been focusing on North America, decides to sell two subsidiaries there as the prolonged coronavirus pandemic further delays commercial manufacturing of plasma products.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Alpha Therapeutic Corporation
- Goetech LLC
- Grifols Therapeutics, Inc.
- MedKeeper
- Talecris Biotherapeutics Inc.
- Haema AG.